Immunotherapy and chemo before surgery for stage III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of immunotherapy (durvalumab) and chemotherapy before surgery or radiation for people with stage III lung cancer that is on the edge of being removable. The goal is to shrink the tumor enough to allow surgery or more effective radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage III non-small cell lung cancer that is borderline resectable (your doctor thinks it might be removable after shrinking it first).
- You cannot have had any prior treatment for your lung cancer, like chemotherapy, radiation, or immunotherapy.
- Your cancer must not have certain gene changes (EGFR or ALK mutations).
- You must be in good enough health to be up and about (ECOG score 0 or 1), and your organs (like kidneys, liver, and bone marrow) must be working well.
- You must be willing to use effective birth control if you or your partner could become pregnant during and for a few months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This study looks at how the body’s immune system responds in people with stage III lung cancer (not removable by surgery) who first get chemotherapy and radiation and then receive the immunotherapy drug durvalumab for one year. It aims to learn more about the immune response and why the treatment works better for some people.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help shrink stage 3 lung cancer and improve outcomes. The goal is to make the tumor easier to remove and possibly lower the chance of it coming back.
This trial studies whether adding durvalumab (an immune therapy) to standard chemoradiation before surgery can improve outcomes for people with stage III, resectable lung cancer. It aims to help shrink the tumor and improve chances of successful treatment.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
This trial tests adding durvalumab (an immunotherapy) after chemotherapy, surgery, and more durvalumab for people with early-stage, operable non-small cell lung cancer. It aims to see if this extra treatment helps prevent the cancer from coming back.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.